Mridula Krishnan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mridula Krishnan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Hall
Department of Clinical Research and Public Health, School of Medicine, Creighton University, Omaha, NE 68124, USA
1 shared publication Apar K Ganti
Department of Internal Medicine, VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA
1 shared publication- Ashley M. Tuin
Creighton University School of Medicine, Omaha, NE, USA
1 shared publication Avyakta Kallam
Division of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, USA
1 shared publication- Benjamin A. Teply
Division of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
1 shared publication - Chandrakanth Are
Division of Surgical Oncology, Department of Surgery, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, USA
1 shared publication
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10346
EGFR Signaling in Colorectal Cancer Metastasis: Molecular Mechanisms and Targeted Therapeutic Strategies
Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide, with metastatic colorectal cancer (mCRC) accounting for most CRC-associated deaths. Despite advances in systemic therapy, mCRC remains associated with poor prognosis because of its molecular heterogeneity, metastatic potential, and the emergence of therapeutic resistance. Improved understanding of the molecular landscape of mCRC has enabled biomarker-driven treatment strategies that have advanced precision oncology. Among the key signaling pathways involved in mCRC, the epidermal growth factor receptor (EGFR) pathway plays a central role in tumor progression and metastasis. EGFR activation triggers the RAS-RAF-MEK-ERK (rat sarcoma-rapidly accelerated fibrosarcoma-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase) and PI3K-AKT-mTOR (phosphoinositide 3-kinase–protein kinase B–mechanistic target of rapamycin) signaling cascades, promoting cellular proliferation, survival, migration, invasion, angiogenesis, and therapeutic resistance. Genetic alterations involving KRAS (kirsten rat sarcoma viral oncogene homolog), NRAS (neuroblastoma rat sarcoma viral oncogene homolog), BRAF (B-Raf proto-oncogene, serine/threonine kinase), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), HER2 (human epidermal growth factor receptor 2), and PTEN (phosphatase and tensin homolog) frequently dysregulate these pathways and serve as predictive biomarkers for targeted therapy. Anti-EGFR monoclonal antibodies have transformed the treatment landscape of mCRC. However, their clinical benefit is frequently limited by intrinsic and acquired resistance mechanisms driven by molecular alterations, pathway redundancy, compensatory signaling, and tumor heterogeneity. This review examines the role of EGFR signaling in CRC metastasis, the molecular alterations affecting EGFR-associated pathways, and the evolving landscape of EGFR-directed and pathway-focused targeted therapies in mCRC.
- 18 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10346
Open AccessEGFR Signaling in Colorectal Cancer Metastasis: Molecular Mechanisms and Targeted Therapeutic Strategies
Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide, with metastatic colorectal cancer (mCRC) accounting for most CRC-associated deaths. Despite advances in systemic therapy, mCRC remains associated with poor prognosis because of its molecular heterogeneity, metastatic potential, and the emergence of therapeutic resistance. Improved understanding of the molecular landscape of mCRC has enabled biomarker-driven treatment strategies that have advanced precision oncology. Among the key signaling pathways involved in mCRC, the epidermal growth factor receptor (EGFR) pathway plays a central role in tumor progression and metastasis. EGFR activation triggers the RAS-RAF-MEK-ERK (rat sarcoma-rapidly accelerated fibrosarcoma-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase) and PI3K-AKT-mTOR (phosphoinositide 3-kinase–protein kinase B–mechanistic target of rapamycin) signaling cascades, promoting cellular proliferation, survival, migration, invasion, angiogenesis, and therapeutic resistance. Genetic alterations involving KRAS (kirsten rat sarcoma viral oncogene homolog), NRAS (neuroblastoma rat sarcoma viral oncogene homolog), BRAF (B-Raf proto-oncogene, serine/threonine kinase), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), HER2 (human epidermal growth factor receptor 2), and PTEN (phosphatase and tensin homolog) frequently dysregulate these pathways and serve as predictive biomarkers for targeted therapy. Anti-EGFR monoclonal antibodies have transformed the treatment landscape of mCRC. However, their clinical benefit is frequently limited by intrinsic and acquired resistance mechanisms driven by molecular alterations, pathway redundancy, compensatory signaling, and tumor heterogeneity. This review examines the role of EGFR signaling in CRC metastasis, the molecular alterations affecting EGFR-associated pathways, and the evolving landscape of EGFR-directed and pathway-focused targeted therapies in mCRC.
- Open Access
Long-Term Survival Rates and Treatment Trends of Burkitt Lymphoma in Patients with HIV—A National Cancer Database (NCDB) Study
Background: Burkitt lymphoma (BL) accounts for 10–35% of AIDS-defining lymphoma in people with HIV (PWH). Previous research consisting of smaller cohorts has shown decreased survival for HIV-associated BL. This study aims to compare overall mortality in BL patients with and without HIV, while investigating impact of treatment modalities in HIV-associated BL. Methods: Using the 2004–2019 NCDB, we identified 4312 patients with stage 3 or 4 BL who had a known HIV status and received either chemotherapy alone or chemotherapy and immunotherapy. Time to death was evaluated using Kaplan–Meier survival estimates. Risk of death was evaluated using an extended multivariable Cox model adjusted for multiple factors and with a Heaviside function for HIV status by time period (0–3 month vs. 3–60 month). Results: Of the 4312 patients included, 1514 (35%) had HIV. For months 0–3 from time of diagnosis, HIV status was not associated with a statistically significant increase in risk of death (HR = 1.04, 95% CI: 0.86, 1.26, p = 0.6648). From month 3to 60, positive HIV status was associated with a 55% increase in risk of death compared to those without HIV (95% CI: 1.38, 1.75, p < 0.0001). Further, this difference in hazard rates (0–3 vs. 3–60) was statistically significant (HR = 1.49, 95% CI: 1.22–1.82, p < 0.001). Conclusions: There is an increased mortality rate from months 3 to 60 in BL patients with HIV compared to patients without HIV. Additionally, risk of death in the first 3 months is significantly decreased by 45% in patients with HIV treated with combination chemotherapy and immunotherapy compared to patients without HIV receiving combination chemotherapy and immunotherapy, providing valuable clinical insight into treatment decision making in the care of HIV-associated BL.
Open AccessLong-Term Survival Rates and Treatment Trends of Burkitt Lymphoma in Patients with HIV—A National Cancer Database (NCDB) Study
Background: Burkitt lymphoma (BL) accounts for 10–35% of AIDS-defining lymphoma in people with HIV (PWH). Previous research consisting of smaller cohorts has shown decreased survival for HIV-associated BL. This study aims to compare overall mortality in BL patients with and without HIV, while investigating impact of treatment modalities in HIV-associated BL. Methods: Using the 2004–2019 NCDB, we identified 4312 patients with stage 3 or 4 BL who had a known HIV status and received either chemotherapy alone or chemotherapy and immunotherapy. Time to death was evaluated using Kaplan–Meier survival estimates. Risk of death was evaluated using an extended multivariable Cox model adjusted for multiple factors and with a Heaviside function for HIV status by time period (0–3 month vs. 3–60 month). Results: Of the 4312 patients included, 1514 (35%) had HIV. For months 0–3 from time of diagnosis, HIV status was not associated with a statistically significant increase in risk of death (HR = 1.04, 95% CI: 0.86, 1.26, p = 0.6648). From month 3to 60, positive HIV status was associated with a 55% increase in risk of death compared to those without HIV (95% CI: 1.38, 1.75, p < 0.0001). Further, this difference in hazard rates (0–3 vs. 3–60) was statistically significant (HR = 1.49, 95% CI: 1.22–1.82, p < 0.001). Conclusions: There is an increased mortality rate from months 3 to 60 in BL patients with HIV compared to patients without HIV. Additionally, risk of death in the first 3 months is significantly decreased by 45% in patients with HIV treated with combination chemotherapy and immunotherapy compared to patients without HIV receiving combination chemotherapy and immunotherapy, providing valuable clinical insight into treatment decision making in the care of HIV-associated BL.
- 1 March 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (3) , 125-126
Immunogenicity of Esophagogastric Cancers: What Is in Line
- 1 March 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (3) , 125-126
Immunogenicity of Esophagogastric Cancers: What Is in Line
- 1 January 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (1) , 35-36
The Evolving Landscape of Pancreatic Cancer
Commentary on evolving landscape of pancreatic cancer #JOP
- 1 January 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (1) , 35-36
The Evolving Landscape of Pancreatic Cancer
Commentary on evolving landscape of pancreatic cancer #JOP
- 1 January 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (1) , e175-e182
Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors
PURPOSE: Clinical trials, which led to the approval of immune checkpoint inhibitors (ICI), have been almost exclusively performed in patients with good Eastern Cooperative Oncology Group performance status (ECOG PS of 0-1). However, ICI remains an attractive option for patients with advanced tumors and poor PS. We hypothesized that patients with ECOG PS ≥ 2 would have worse outcomes with ICI. METHODS: We retrospectively identified patients with advanced solid tumors who were treated with ICI at our institution. The log-rank test compared the survival among patients with different ECOG PS. We used a proportional hazards model to assess association between ECOG PS and overall survival (OS) with adjustment for covariates including age, sex, malignancy type, time from advance disease diagnosis, and line of therapy. We compared overall response rates between groups with Pearson chi-square exact test. We also analyzed in-hospital mortality and hospice referral rates. RESULTS: We identified 257 patients treated with ICI. One hundred eighty-two patients had ECOG PS 0-1, and 75 had ECOG PS ≥ 2. The median overall survival was 12.6 months for the ECOG PS 0-1 group compared with 3.1 months for the ECOG PS ≥ 2 group ( P < .001). The overall response rate for patients with ECOG PS 0-1 was 23% compared with 8% for those with poor PS ( P = .005). Patients with poor PS treated with ICI had similar hospice referral rates (67% for ECOG PS ≥ 2 v 61.9% for ECOG PS 0-1, P = .50) but were more likely to have in-hospital death as compared with the good PS group (28.6% v 15.1%, P = .035). CONCLUSION: Despite the appeal of ICI in patients with advanced malignancy and poor PS, outcomes in this cohort were poor. Prospective trials defining the activity and role of ICI in poor PS are urgently needed.
- 1 January 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (1) , e175-e182
Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors
PURPOSE: Clinical trials, which led to the approval of immune checkpoint inhibitors (ICI), have been almost exclusively performed in patients with good Eastern Cooperative Oncology Group performance status (ECOG PS of 0-1). However, ICI remains an attractive option for patients with advanced tumors and poor PS. We hypothesized that patients with ECOG PS ≥ 2 would have worse outcomes with ICI. METHODS: We retrospectively identified patients with advanced solid tumors who were treated with ICI at our institution. The log-rank test compared the survival among patients with different ECOG PS. We used a proportional hazards model to assess association between ECOG PS and overall survival (OS) with adjustment for covariates including age, sex, malignancy type, time from advance disease diagnosis, and line of therapy. We compared overall response rates between groups with Pearson chi-square exact test. We also analyzed in-hospital mortality and hospice referral rates. RESULTS: We identified 257 patients treated with ICI. One hundred eighty-two patients had ECOG PS 0-1, and 75 had ECOG PS ≥ 2. The median overall survival was 12.6 months for the ECOG PS 0-1 group compared with 3.1 months for the ECOG PS ≥ 2 group ( P < .001). The overall response rate for patients with ECOG PS 0-1 was 23% compared with 8% for those with poor PS ( P = .005). Patients with poor PS treated with ICI had similar hospice referral rates (67% for ECOG PS ≥ 2 v 61.9% for ECOG PS 0-1, P = .50) but were more likely to have in-hospital death as compared with the good PS group (28.6% v 15.1%, P = .035). CONCLUSION: Despite the appeal of ICI in patients with advanced malignancy and poor PS, outcomes in this cohort were poor. Prospective trials defining the activity and role of ICI in poor PS are urgently needed.
- 20 October 2021
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (2) , 335-340
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma
Peripheral T-cell lymphomas (PTCL) are a unique subset of lymphomas with a poor prognosis due to limited treatment options. We performed a phase 1 study of carfilzomib in patients with relapsed/refractory PTCL to determine the safety profile and the maximum tolerated dose (MTD) of this agent. The study was a classical 3 + 3 phase 1 design with intra-patient dose escalation allowed beginning on day 8 of cycle 1 and subsequently. Dose-limiting toxicity (DLT) was defined as the occurrence of any grade 3/4 adverse event. Carfilzomib was given on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Fifteen patients were enrolled from 3 centers. The median age of patients was 62. The median number of prior therapies for subjects on this trial was five. The MTD of carfilzomib was 36 mg/m2. Dose-limiting toxicities included anemia and sepsis. Serious adverse events were seen in 45% of patients. Single-agent carfilzomib leads to a complete response in one patient and a partial response in one patient. Overall, the drug was reasonably tolerated for a heavily pretreated population, but the limited response rate and short duration of response demonstrate a lack of promise for carfilzomib as a single agent in this patient population.
- 20 October 2021
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (2) , 335-340
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma
Peripheral T-cell lymphomas (PTCL) are a unique subset of lymphomas with a poor prognosis due to limited treatment options. We performed a phase 1 study of carfilzomib in patients with relapsed/refractory PTCL to determine the safety profile and the maximum tolerated dose (MTD) of this agent. The study was a classical 3 + 3 phase 1 design with intra-patient dose escalation allowed beginning on day 8 of cycle 1 and subsequently. Dose-limiting toxicity (DLT) was defined as the occurrence of any grade 3/4 adverse event. Carfilzomib was given on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Fifteen patients were enrolled from 3 centers. The median age of patients was 62. The median number of prior therapies for subjects on this trial was five. The MTD of carfilzomib was 36 mg/m2. Dose-limiting toxicities included anemia and sepsis. Serious adverse events were seen in 45% of patients. Single-agent carfilzomib leads to a complete response in one patient and a partial response in one patient. Overall, the drug was reasonably tolerated for a heavily pretreated population, but the limited response rate and short duration of response demonstrate a lack of promise for carfilzomib as a single agent in this patient population.
- 4 June 2019
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 25 (7) , 1712-1718
The role of targeted therapy in thymic carcinoma
Thymic carcinoma is a rare entity and can be distinguished from benign thymomas by their aggressive nature and poor prognosis. The National Comprehensive Cancer Network guidelines recommend resection followed by adjuvant platinum-based chemotherapy for resectable tumors. However, the outcomes for metastatic or relapsed thymic carcinomas are poor with no regimen showing a consistent benefit. Moreover, the relative rarity of these tumors makes clinical trials difficult. Molecular analysis of thymomas shows a high incidence of genetic mutations and targeted therapy holds promise. We will briefly outline and review the current role of targeted therapy in thymic cancer.
- 4 June 2019
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 25 (7) , 1712-1718
The role of targeted therapy in thymic carcinoma
Thymic carcinoma is a rare entity and can be distinguished from benign thymomas by their aggressive nature and poor prognosis. The National Comprehensive Cancer Network guidelines recommend resection followed by adjuvant platinum-based chemotherapy for resectable tumors. However, the outcomes for metastatic or relapsed thymic carcinomas are poor with no regimen showing a consistent benefit. Moreover, the relative rarity of these tumors makes clinical trials difficult. Molecular analysis of thymomas shows a high incidence of genetic mutations and targeted therapy holds promise. We will briefly outline and review the current role of targeted therapy in thymic cancer.
- Open Access
- 26 September 2016
- Published by Wiley in Case Reports in Rheumatology
- Vol. 2016, 1-3
Adult Onset Henoch-Schonlein Purpura and Intussusception: A Rare Presentation
We present an unusual case of a young 26-year-old male who was diagnosed with Henoch-Schonlein Purpura (HSP). Initial presentation was primarily mild gastrointestinal symptoms, which progressed to a life threatening intussusception and subsequently resolved with prompt glucocorticoid use rather than typical surgical intervention. Of importance, the patient’s initial gastrointestinal symptoms without associated skin manifestations made the diagnosis difficult. In conclusion, it is important to recognize uncommon presentations of HSP as it may lead to life threatening complications and surgical intervention may be avoided with prompt treatment.
- 26 September 2016
- Published by Wiley in Case Reports in Rheumatology
- Vol. 2016, 1-3
Open AccessAdult Onset Henoch-Schonlein Purpura and Intussusception: A Rare Presentation
We present an unusual case of a young 26-year-old male who was diagnosed with Henoch-Schonlein Purpura (HSP). Initial presentation was primarily mild gastrointestinal symptoms, which progressed to a life threatening intussusception and subsequently resolved with prompt glucocorticoid use rather than typical surgical intervention. Of importance, the patient’s initial gastrointestinal symptoms without associated skin manifestations made the diagnosis difficult. In conclusion, it is important to recognize uncommon presentations of HSP as it may lead to life threatening complications and surgical intervention may be avoided with prompt treatment.